IL152782A0 - S-methyl-dihydro-ziprasidone for treatment of psychiatric and ocular disorders - Google Patents

S-methyl-dihydro-ziprasidone for treatment of psychiatric and ocular disorders

Info

Publication number
IL152782A0
IL152782A0 IL15278201A IL15278201A IL152782A0 IL 152782 A0 IL152782 A0 IL 152782A0 IL 15278201 A IL15278201 A IL 15278201A IL 15278201 A IL15278201 A IL 15278201A IL 152782 A0 IL152782 A0 IL 152782A0
Authority
IL
Israel
Prior art keywords
ziprasidone
psychiatric
dihydro
methyl
treatment
Prior art date
Application number
IL15278201A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26903852&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL152782(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of IL152782A0 publication Critical patent/IL152782A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL15278201A 2000-06-02 2001-05-28 S-methyl-dihydro-ziprasidone for treatment of psychiatric and ocular disorders IL152782A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20913600P 2000-06-02 2000-06-02
US21217200P 2000-06-16 2000-06-16
PCT/IB2001/000933 WO2001091756A2 (en) 2000-06-02 2001-05-28 S-methyl-dihydro-ziprasidone for treatment of psychiatric and ocular disorders

Publications (1)

Publication Number Publication Date
IL152782A0 true IL152782A0 (en) 2003-06-24

Family

ID=26903852

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15278201A IL152782A0 (en) 2000-06-02 2001-05-28 S-methyl-dihydro-ziprasidone for treatment of psychiatric and ocular disorders
IL152782A IL152782A (en) 2000-06-02 2002-11-11 S-methyl-dihydro-ziprasidone for the treatment of psychiatric disorders and eye disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL152782A IL152782A (en) 2000-06-02 2002-11-11 S-methyl-dihydro-ziprasidone for the treatment of psychiatric disorders and eye disorders

Country Status (44)

Country Link
US (1) US20060287336A1 (de)
EP (3) EP1468686B1 (de)
JP (2) JP2003534381A (de)
KR (1) KR20030007824A (de)
CN (1) CN1431901A (de)
AP (2) AP1747A (de)
AR (1) AR028937A1 (de)
AT (3) ATE343387T1 (de)
AU (1) AU2001258690A1 (de)
BG (1) BG107267A (de)
BR (1) BR0111271A (de)
CA (1) CA2410618A1 (de)
CY (1) CY1105992T1 (de)
CZ (1) CZ20023860A3 (de)
DE (3) DE60124791T2 (de)
DK (1) DK1468686T3 (de)
DO (1) DOP2001000181A (de)
EA (1) EA007068B1 (de)
EC (1) ECSP024369A (de)
EE (1) EE200200670A (de)
ES (1) ES2277170T3 (de)
GE (1) GEP20053512B (de)
HN (1) HN2001000119A (de)
HR (1) HRP20020953A2 (de)
HU (1) HUP0301747A2 (de)
IL (2) IL152782A0 (de)
IS (1) IS6619A (de)
MA (1) MA26908A1 (de)
MX (1) MXPA02011862A (de)
NO (1) NO325077B1 (de)
NZ (1) NZ551012A (de)
OA (1) OA12267A (de)
PA (1) PA8518301A1 (de)
PE (1) PE20011329A1 (de)
PL (1) PL365576A1 (de)
PT (2) PT1698338E (de)
SI (1) SI1468686T1 (de)
SK (1) SK16622002A3 (de)
SV (1) SV2002000473A (de)
UA (1) UA79425C2 (de)
UY (1) UY26742A1 (de)
WO (1) WO2001091756A2 (de)
YU (1) YU90702A (de)
ZA (1) ZA200209665B (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7419493B2 (en) 2002-12-13 2008-09-02 Regents Of The University Of Minnesota Scleral depressor
WO2005040160A2 (en) 2003-10-24 2005-05-06 Teva Pharmaceutical Industries Ltd. Processes for preparation of ziprasidone
ES2250001B1 (es) * 2004-09-29 2007-06-01 Medichem, S.A. Proceso para la purificacion de ziprasidona.
JP2012174228A (ja) * 2011-02-24 2012-09-10 Kyocera Corp プログラム保護装置および通信装置
EP3610890A1 (de) 2012-11-14 2020-02-19 The Johns Hopkins University Verfahren und zusammensetzungen zur behandlung von schizophrenie
US9981041B2 (en) * 2016-08-23 2018-05-29 Ira Jason Salzman Ophthalmic lubricating spray

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW491847B (en) * 1996-05-07 2002-06-21 Pfizer Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
NZ332219A (en) * 1996-05-07 2005-02-25 Pfizer Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2(1H)-indol-2-one (ziprasidone), its preparation and its use as dopamine D2 antagonist
PT985414E (pt) * 1998-05-26 2004-01-30 Pfizer Prod Inc Metodo de tratamento de glaucoma e retinopatia isquemica
AU4062900A (en) * 1999-04-06 2000-10-23 Sepracor, Inc. Methods and compositions for the treatment of neuroleptic and related disorders using ziprasidone metabolites

Also Published As

Publication number Publication date
SV2002000473A (es) 2002-10-24
SI1468686T1 (sl) 2007-04-30
EP1468686A3 (de) 2004-12-01
ES2277170T3 (es) 2007-07-01
CZ20023860A3 (cs) 2004-01-14
YU90702A (sh) 2005-11-28
DE60133596D1 (de) 2008-05-21
CY1105992T1 (el) 2011-04-06
PE20011329A1 (es) 2002-01-15
EP1286672B1 (de) 2006-10-25
EE200200670A (et) 2004-08-16
ATE391507T1 (de) 2008-04-15
GEP20053512B (en) 2005-05-10
PT1468686E (pt) 2007-01-31
PT1698338E (pt) 2008-06-03
IS6619A (is) 2002-11-14
BR0111271A (pt) 2003-06-10
UA79425C2 (en) 2007-06-25
AU2001258690A1 (en) 2001-12-11
NO20025760D0 (no) 2002-11-29
HRP20020953A2 (en) 2005-02-28
EA200201168A1 (ru) 2003-06-26
NO325077B1 (no) 2008-01-28
HUP0301747A2 (hu) 2003-09-29
WO2001091756A3 (en) 2002-09-26
JP2008056700A (ja) 2008-03-13
IL152782A (en) 2007-10-31
EA007068B1 (ru) 2006-06-30
AR028937A1 (es) 2003-05-28
NO20025760L (no) 2003-01-15
US20060287336A1 (en) 2006-12-21
DE60124093D1 (de) 2006-12-07
DK1468686T3 (da) 2007-03-12
AP1831A (en) 2008-02-26
AP2005003272A0 (en) 2005-03-31
CN1431901A (zh) 2003-07-23
EP1698338A3 (de) 2006-09-20
ZA200209665B (en) 2003-11-28
EP1698338B1 (de) 2008-04-09
BG107267A (bg) 2003-06-30
MA26908A1 (fr) 2004-12-20
DE60124791D1 (de) 2007-01-04
EP1698338A2 (de) 2006-09-06
KR20030007824A (ko) 2003-01-23
EP1286672A2 (de) 2003-03-05
AP1747A (en) 2007-05-31
HN2001000119A (es) 2001-09-11
SK16622002A3 (sk) 2004-07-07
EP1468686B1 (de) 2006-11-22
WO2001091756A2 (en) 2001-12-06
MXPA02011862A (es) 2003-04-10
NZ551012A (en) 2008-04-30
UY26742A1 (es) 2001-12-28
ECSP024369A (es) 2003-02-06
EP1468686A2 (de) 2004-10-20
PA8518301A1 (es) 2002-09-17
PL365576A1 (en) 2005-01-10
OA12267A (en) 2004-01-20
ATE343387T1 (de) 2006-11-15
JP2003534381A (ja) 2003-11-18
DOP2001000181A (es) 2002-04-15
DE60124791T2 (de) 2007-09-13
ATE345818T1 (de) 2006-12-15
CA2410618A1 (en) 2001-12-06

Similar Documents

Publication Publication Date Title
GB0007193D0 (en) Treatment of movrmrnt disorders
HUP0400914A3 (en) Methods of treatment of mitochondrial disorders
IL153425A0 (en) Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders
IL155589A0 (en) Novel amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful for the treatment of nervous system disorders
IL151890A0 (en) Hydroxyphenyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
IL156340A0 (en) 3-indoline derivatives useful in the treatment of psychiatric and neurologic disorders
AU2001271887A1 (en) Methods for diagnosis and treatment of psychiatric disorders
HUP0302718A3 (en) Methods and compositions for the treatment of diseases of the eye
AU2001256855A1 (en) Preparation for the prevention and treatment of ocular disorders
IL155433A0 (en) Treatment of t cell disorders
IL151765A0 (en) Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives for the treatment of pain
IL151891A0 (en) Quinolinyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
AU2002362115A8 (en) Composition and methods for treatment of neurological disorders
GB9926968D0 (en) Treatment of neurological disorders
IL155874A0 (en) Treatment of anxiety disorders
IL152782A0 (en) S-methyl-dihydro-ziprasidone for treatment of psychiatric and ocular disorders
GB2360453B (en) Treatment of skin conditions
IL140540A0 (en) Treatment of anxiety disorders
AR026062A1 (es) Tratamiento de desordenes oculares
GB9901808D0 (en) Drugs for treatment of psychiatric and brain disorders
AU2001236909A1 (en) Method of treating disorders of the eye
GB0029955D0 (en) Treatment of neuropsychiatric disorders
GB0017951D0 (en) Treatment of movement disorders
GB9924942D0 (en) Treatment of movement disorders
AU2002310292A1 (en) Novel treatment for neurological and psychiatric disorders

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed